Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET
Company Participants
Jon Patton – Director of Investor Relations and Communication
Wayne Pisano – Chair of Oncolytics’ Board of Directors and Interim Chief Executive Officer
Thomas Heineman – Chief Medical Officer
Christophe Degois – Vice President of Business Development
Kirk Look – Chief Financial Officer
Conference Call Participants
Soumit Roy – JonesTrading Institutional Services
Louise Chen – Cantor Fitzgerald & Co.
Michael Freeman – Raymond James
Operator
Good afternoon and welcome to Oncolytics Biotech’s Third Quarter 2024 Conference Call. All participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company’s request.
I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communication. Please go ahead.
Jon Patton
Thank you, operator and thank you all for joining us. After remarks from company management, we will open the call for Q&A. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company’s business prospects and the development and commercialization of pelareorep, including statements regarding the company’s mission, strategy and milestones, the company’s belief as to the potential and mechanism of action of pelareorep as a cancer therapeutic, our potential registrational opportunities for pelareorep and our plans and strategies related thereto, our plan to continue enrollment in GOBLET cohort 5, our ongoing business development initiatives and other statements related to anticipated developments in the company’s business.
These statements are based on management’s current expectations and beliefs and are subject to a number of factors, which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of
Read the full article here
